Clinical Trials Logo

Abnormal Karyotype clinical trials

View clinical trials related to Abnormal Karyotype.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01383447 Terminated - Clinical trials for Recurrent Adult Acute Lymphoblastic Leukemia

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Start date: October 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of entinostat when given together with imatinib mesylate and to see how well it works in treating patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Entinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT01066468 Terminated - Clinical trials for Chronic Myeloid Leukemia (CML)

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens

NCT ID: NCT00860535 Terminated - Clinical trials for Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)

Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

Start date: June 2009
Phase: Phase 1
Study type: Interventional

This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.

NCT ID: NCT00500006 Terminated - Clinical trials for Chronic Myelogenous Leukemia

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Start date: October 2007
Phase: Phase 1
Study type: Interventional

This study will evaluate MK0457 in combination with Dasatinib in patients with Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Efficacy and Safety will be evaluated.

NCT ID: NCT00464113 Terminated - Clinical trials for Chronic Myeloid Leukemia

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Start date: May 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.